Stem Cell Market Is The Accelerating Growth By R&D Efforts

---

Table of Content

The size of the global stem cell market is set to hit almost USD 17.79 billion by the end of 2027 and is poised to grow at a CAGR of 8.61% between 2020 and 2027.

The number of facilities producing cell therapies and the increase in clinical trials, which account for the majority of global healthcare spending, is driving the expansion of the stem cell market.

Market Overview:

Stem cells, are undifferentiated cells that can replicate and give rise to both stem cells that will remain and differentiate (become specialized). Stem cells are of tremendous interest because they can be utilized to create treatments to replace cells that have been destroyed or dysfunctional due to several illnesses and injuries, including Parkinson's disease, heart disease, and diabetes.

The increase in research activities concentrating on the creation, storage, and characterization of stem cells in addition to the expansion of the industry in terms of revenue as a consequence of increased demand for stem cell banking. Technology developments in the parent and auxiliary markets for stem cell usage represent other aspects that promote the predicted rise in demand for stem cells throughout the projected timeframe. For instance, Cellino Biotech, a manufacturer of cell treatment products, obtained USD 80 million in a Series A investment round in January 2022. By constructing the first autonomous human cell foundry in 2025, Cellino hopes to increase access to stem cell-based medicines.

Report Highlight:

• By Product, According to their kind, adult stem cells, human embryonic stem cells, minuscule embryonic-like stem cells, and induced pluripotent stem cells make up the majority of the global stem cell industry.  Adult stem cells, which will have the largest market share of XX% in 2022, are in contrast to embryonic stem cells, which need the death of embryos. Moreover, there is no risk of graft rejection when employing adult stem cells. The growth of cell banking services and advancements in biopreservation and cryopreservation are expected to result in an even greater rise in the demand for adult stem cells.  Less ethical debate surrounds adult cells, which fosters the market's expansion.
• By Application, Oncology saw the fastest growth in terms of application categories due to the numerous therapies for cancer and tumors that are currently being developed. Due to a rise in clinical trials using stem cell therapies that target various ailments, regenerative medicine will have a larger market share of XX% in 2022.
• Also, several countries are investing heavily in the development of regenerative medicines. For instance, the Canadian government provided about USD 6.9 million for regenerative medicine research in March 2020. This fund will finance four clinical trials and nine translational studies intended to create novel regenerative medicine therapies.
• By Technology, The cell acquisition category held the top position in 2022 with XX% of the market's sales. The discovery of embryonic stem cells has made it feasible to develop novel therapies for several disorders. These cells can be employed to differentiate different bodily cell types due to their pluripotent nature. Yet, taking embryonic cells straight from the embryo has moral repercussions. iPS cells were shown to be a potential replacement as a result. For instance, a team of researchers from Singapore and Australia worked together in September 2020 to look at the molecular changes that take place when adult skin cells develop into induced pluripotent stem cells (iPSCs).
• By Therapy, Allogeneic treatment had the largest market share among the various therapeutic subcategories in 2020. The advantage of using allogeneic stem cells is that they produce their immune cells, which can help in the clearance of any cancer cells that could still be present after high-dose treatment.  This anti-cancer graft's main objective is to stop cancer from returning. Addictions to cancer are becoming more common; they often take place a year after therapy and are more common in young people, those with oropharyngeal cancer, and those with breast cancer.  The market for allergy medications has expanded more swiftly as a result of these qualities.

Stem Cell Market Report Scope

Regional Insight:

North America, which overall controlled the business, received the largest share of the worldwide stem cell market from the United States. In the US and Canada, comprehensive healthcare systems are in place. Also, these platforms aid in research and innovation. The growing number of cancer patients is creating opportunities for industry participants. The leading market players are concentrating their R&D efforts on developing novel stem cell therapies. In addition, the American Cancer Society predicts that in 2022 there will be 1,918,030 new instances of cancer in the country, along with 609,360 recorded fatalities.

In contrast, the Asia Pacific region is expected to expand at a quick rate of XX% CAGR between 2023 and 2032 as a result of robust product pipelines for stem cell-based treatments and a sizable patient pool. Due to the rising prevalence of illnesses such as cancer, neurological disorders, and diabetes, the stem cell industry is expected to expand quickly. Government financing to speed up research on stem cells is another factor supporting this region's development.

Market Dynamics

Drivers

Spread knowledge on stem cell preservation

The exciting idea behind the expanding stem cell banking industry is to keep stem cells at their peak potency until they are potentially needed later in life to fight disease. A business that includes the preservation of adult stem cells is mushrooming around the banking of stem cells from a baby's umbilical cord blood and tissue. One day, those adult stem cells might be applied in regenerative medicine treatments. Compared to stem cells from other sources, such as the bone marrow, umbilical cord stem cells are more youthful and active, which allows them to differentiate more quickly. Consider it the main template.

Restraints

High operational cost of stem cell banking

Throughout the projected period, the market for stem cell banking will face significant challenges due to its high operating expenses. Patients are unable to pay these costs, which prevents new suppliers from entering the market. processing the sample, evaluating its quality and ability to be preserved, and storing it. They are not covered by the cost of buying and maintaining expensive instruments, reagents, and consumables. As a result, service providers incur substantial operational costs.

Opportunity

R&D efforts to create stem cell treatments are expanding.

The pharmaceutical and biopharmaceutical industries will considerably accelerate the market's growth throughout the forecast period by increasing their stem cell-based research and development.  Growing R&D efforts to develop stem cell therapies, rising approvals for clinical trials in stem cell research and factors including increased awareness of umbilical cord stem cells and the rising desire for regenerative treatment options are all contributing to the market's expansion.

Challenge 

Scale-up manufacturing restrictions on a technical level

Manufacturers find it extremely difficult to scale up their stem cell production capabilities because of the technical difficulties involved with multiple manufacturing steps, such as stem cell identification, isolation, storage, and preservation.

Recent Development:

• April 2022, The Stem Cell SpaceShot Grant, created by TreeFrog Therapeutics, provides US$100,000 in research support in the fields of stem cell biology and regenerative medicine.
• September2021, In collaboration with WiCell®, STEMCELL Technologies introduced human pluripotent stem cell (hPSC) characterization and banking services. Researchers will receive thorough cell quality assessments from these services, provided by STEMCELL's Contract Assay Services division, and will be able to create cell banks using standardized procedures.

Major Key Players:

• STEMCELL Technologies, Inc.
• Osiris Therapeutics, Inc.
• Cynata Therapeutics
• Human Longevity, Inc.
• Advanced Cell Technology, Inc.
• BIOTIME, Inc.
• Mesoblast Limited
• Promethera Biosciences S.A. / N.V.
• Merck Group
• Takara Bio Group

Market Segmentation

By Product

• Adult Stem Cells
  • Neuronal Stem Cells
  • Mesenchymal Stem Cells
  • Dental Stem Cells
  • Umbilical Cord Stem Cells
  • Adipose-derived Stem Cells
  • HematopoieticStem Cells
  • Dedifferentiated fat (DFAT) Cells
  • Other ASC’s
• Very Small Embryonic Like Stem Cells
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells

By Application

• Regenerative Medicine
  • Neurology
  • Oncology
  • Hematology
  • Injuries
  • Orthopedics
  • Incontinence
  • Diabetes
  • Liver Disorder
  • Others
• Drug Discovery and development

By Technology

• Cell Acquisition
  • Apheresis
  • Bone Marrow Harvest
  • Umbilical Blood Cord
• Cryopreservation
  • Cell production
  • Therapeutic Cloning
  • Cell Culture
  • In-Vitro fertilization
  • Isolation
• Expansion and Sub-Culture

By Therapy

• Allogenic Stem Cell Therapy
• Autologous Stem Cell Therapy

Buy this Research Report@ https://www.precedenceresearch.com/checkout/1118

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com| +1 9197 992 333